Company profile: Vivani Medical
1.1 - Company Overview
Company description
- Provider of implantable visual prosthetics for blind individuals and developer of NanoPortal technology for miniature, subdermal drug implants delivering steady medication, including NPM-115 for chronic weight management and NPM-119 (under development) for type 2 diabetes; via subsidiary Cortigent, develops targeted neurostimulation for artificial vision and muscle movement restoration in stroke rehabilitation.
Products and services
- Cortigent: Targeted neurostimulation systems help patients recover critical body functions, delivering artificial vision and enabling muscle movement restoration during stroke rehabilitation
- NanoPortal™ Technology: Miniature platform architects subdermal drug implants that steadily deliver medication over extended periods, aiming to improve adherence and tolerability for long-term therapy
- NPM-115: Subdermal, high-dose exenatide implant delivers steady medication for chronic weight management for up to six months, maintaining consistent exposure to improve tolerability
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vivani Medical
Lexaria Bioscience
HQ: Canada
Website
- Description: Provider of patented DehydraTECH technology that improves bio-absorption, reduces onset time, and enhances delivery of lipophilic drugs across the blood-brain barrier; out-licenses this platform and operates units focused on pharmaceuticals (hypertension, antiviral, epilepsy), oral non-combusted nicotine, hemp-derived ingredients, a Health Canada licensed lab for cannabinoid and other formulations, and nutraceutical CPG applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lexaria Bioscience company profile →
Incline Therapeutics
HQ: United States
Website
- Description: Provider of hospital-focused specialty pharmaceutical solutions, developing IONSYS (fentanyl iontophoretic transdermal system), a pharmaceutical device for the treatment of post-operative pain in hospital settings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Incline Therapeutics company profile →
Lipocine
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products, including TLANDO, an FDA-approved oral testosterone replacement therapy; LPCN 1111, an oral testosterone prodrug for hypogonadal men; LPCN 1144 and 1148, oral prodrugs of bioidentical testosterone for NASH and cirrhosis symptoms; LPCN 1107, an oral candidate to prevent recurrent preterm birth (FDA orphan drug); and LPCN 1154, an oral neurosteroid for postpartum depression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lipocine company profile →
Suono Bio
HQ: United States
Website
- Description: Provider of ultrasound-mediated drug delivery platforms enabling ultra-rapid delivery of small molecules, biologics, and nucleic acids to the gastrointestinal tract and directly into cells without encapsulation; offerings include Ultrasonic Enhanced Delivery and SuonoCalm for treating inflammatory conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Suono Bio company profile →
Cellics Therapeutics
HQ: United States
Website
- Description: Provider of biomimetic nanomedicines based on cellular nanosponges—nanoparticles coated with cell membranes—to bind and neutralize bacterial toxins, cytokines, and viruses. Products include CTI-005, a red blood cell nanosponge for MRSA pneumonia, and CTI-111, a macrophage nanosponge for sepsis that absorbs and neutralizes toxins and inflammatory cytokines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cellics Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vivani Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vivani Medical
2.2 - Growth funds investing in similar companies to Vivani Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vivani Medical
4.2 - Public trading comparable groups for Vivani Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →